Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Apoptosis
    (9)
  • Aurora Kinase
    (5)
  • Autophagy
    (2)
  • CDK
    (4)
  • FLT
    (2)
  • PDGFR
    (2)
  • PI3K
    (3)
  • PLK
    (24)
  • Serine/threonin kinase
    (2)
  • Others
    (27)
Filter
Search Result
Results for "PLK1 Inhibitor" in TargetMol Product Catalog
  • Inhibitor Products
    57
    TargetMol | Activity
  • Natural Products
    2
    TargetMol | inventory
MLN0905
T27041228960-69-7
MLN0905 (PLK1 Inhibitor) is an effective PLK1 inhibitor(IC50=2 nM).
  • $68
In Stock
Size
QTY
Onvansertib
T62471034616-18-6
Onvansertib (NMS-1286937), an oral, specific Polo-like Kinase 1 (PLK1) inhibitor, is with IC50 of 2 nM. The specificity of NMS-P937 forPLK1 is 5000-fold higher over PLK2/PLK3.
  • $39
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
T521
T28904891020-54-5In house
T521 is a selective inhibitor of the PBD of Plk1 and shows no inhibitory effect on Plk2 and Plk3.
  • $410
In Stock
Size
QTY
Poloxin-2
T25969321695-37-8In house
Poloxin-2 is a potent and selective Plk1 PBD inhibitor with anti-tumour activity that reduces the protein level of Plk1 in HeLa cells.
  • $350
In Stock
Size
QTY
CCB02
T107042100864-57-9In house
CCB02 is a selective CPAP-tubulin interaction inhibitor (IC50: 689 nM) with anti-tumor activity. CCB02 shows no inhibition on the cell cycle- and centrosome-related kinases, or the phosphorylation status of Aurora-A, CDK2, Plk1, Plk2, and CHK1.
  • $117
In Stock
Size
QTY
TargetMol | Inhibitor Sale
3MB-PP1
T21678956025-83-5In house
3MB-PP1 is a bulky purine analog and a Polo-like kinase 1 (Plk1) inhibitor. In cells expressing analog-sensitive Plk1 alleles, 3MB-PP1 blocks mitotic progression and cell division arise by targeting Plk1. 3MB-PP1 specifically inhibits analog-sensitive Ssn3 (Cdk8). 3MB-PP1 inhibits Leu93 Mutant Zipper-interacting protein kinase with IC50 of 2 μM. 3MB-PP1 can be used for the research of cell division and hypha formation of Candida albicans.
  • $48
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Plogosertib
T713991137212-79-3In house
Plogosertib (CYC140) is an orally active, selective, potent, and ATP-competitive PLK1 inhibitor with an IC50 value of 3 nM.Plogosertib exhibits antiproliferative and anticancer activity and can be used for the study of solid and hematologic tumors. and hematologic tumors.
  • $228
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Wortmannin
T628319545-26-7
Wortmannin (SL-2052) is a PI3K inhibitor (IC50=3 nM) that is covalent and irreversible. Wortmannin is also an inhibitor of PlK1 and PlK3 (IC50=5.8/48 nM) that blocks autophagy.
  • $32
In Stock
Size
QTY
TargetMol | Citations Cited
BI 2536
T6173755038-02-9
BI2536 is an effective Plk1 inhibitor (IC50: 0.83 nM). It has 4- and 11-fold greater selectivity than Plk2 and Plk3.
  • $38
In Stock
Size
QTY
TargetMol | Citations Cited
PLK1/p38γ-IN-1
T814412418614-81-8
PLK1/p38γ-IN-1 (compound 14) serves as a dual inhibitor targeting both PLK1 and p38γ kinases, effectively suppressing the proliferation of human hepatocellular carcinoma and hepatoblastoma cell lines in vitro [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
PLK1-IN-7
T814402938910-96-2
PLK1-IN-7 (compound 30e) is a potent inhibitor exhibiting an IC50 value of 0.66 nM and demonstrates significant antiproliferative and antitumor activities [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Cyclapolin 9
T2270040533-25-3
Cyclapolin 9 is a selective, potent, and ATP-competitive inhibitor of polo-like kinase 1 (PLK1) with an IC50 of 500 nM, and has not shown activity against other kinases.
  • $93
In Stock
Size
QTY
PLK1-IN-6
T74777
PLK1-IN-6, a potent and selective inhibitor of PLK1, demonstrates significant anti-proliferative activities against cancer cells with an IC50 value of 0.45 nM [1].
  • Inquiry Price
Size
QTY
PLK1-IN-2
T402652640254-52-8
PLK1-IN-2 is a PLK1 kinase inhibitor with an IC 50 value of 0.384 μM.
  • $970
Backorder
Size
QTY
PHA-680632
T6338398493-79-3
PHA-680632 is potent inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 27 nM, 135 nM and 120 nM, respectively. It has 10- to 200-fold higher IC50 for FGFR1, FLT3, LCK, PLK1, STLK2, and VEGFR2/3.
  • $39
In Stock
Size
QTY
PHA-767491 hydrochloride
T6940942425-68-5
PHA-767491 hydrochloride (CAY-10572 hydrochloride) is an effective ATP-competitive dual Cdc7/CDK9 inhibitor (IC50: 10/34 nM). It has ~20-fold selectivity against GSK3-β and CDK1/2, 50-fold selectivity against CDK5 and MK2, 100-fold selectivity against CHK2 and PLK1.
  • $43
In Stock
Size
QTY
MCC1019
T6949629115-34-2
MCC1019 is a novel selective inhibitor of the Polo-box domain of Polo-like kinase 1 (PLK1).
  • $1,520
6-8 weeks
Size
QTY
TAK-960
T72001137868-52-0
TAK-960 is an orally bioavailable, selective inhibitor of Plks with IC50 values of 0.8, 16.9, and 50.2 nM for Plk1, Plk2, and Plk3, respectively.
  • $58
In Stock
Size
QTY
TAK-960 hydrochloride
T642161137868-96-2
TAK-960 hydrochloride is a potent, selective, orally active inhibitor of polo-like kinase 1 (PLK1) (IC50: 0.8 nM). TAK-960 hydrochloride inhibits the proliferation of a variety of tumour cell lines and significantly treats a variety of tumour xenografts.
  • $1,520
8-10 weeks
Size
QTY
MK-1496
T715561037254-47-9
MK1496 is a n orally bioavailable Polo-like kinase 1 (Plk1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor MK1496 selectively inhibits Plk1, inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).
  • $1,520
6-8 weeks
Size
QTY
Dihydrobaicalein
TN384835683-17-1
Dihydrobaicalein is a natural product from Scutellaria baicalensis, a PLK1 inhibitor (IC50:6.3 μM).Dihydrobaicalein inhibits VRK2 and PLK2.
  • $195
In Stock
Size
QTY
PLK1-IN-4
T638862622273-55-4
PLK1-IN-4 is a potent and selective inhibitor of PLK1 (IC50<0.508 nM). PLK1-IN-4 exhibits broad anti-proliferative effects on a wide range of cancer cells. PLK1-IN-4 is able to block the cell cycle in G2/M phase and induce apoptosis in cancer cells. carcinoma.
  • $1,520
8-10 weeks
Size
QTY
Poloxime
T1655917302-61-3
Poloxime is a hydrolysis product of poloxin and is a non-ATP-competitive Plk1 inhibitor. It also has moderate Plk1 inhibitory activity.
  • $39
5 days
Size
QTY
JH295
T387101311143-71-1
JH295 is a highly potent and selective inhibitor of NIMA-related kinase 2 (Nek2), exhibiting irreversible inhibition activity with an IC 50 value of 770 nM. This compound effectively inhibits cellular Nek2 using the alkylation of Cys22. Importantly, JH295 does not exhibit any inhibitory effects toward Cdk1, Aurora B, or Plk1, which are kinases involved in mitotic processes. Furthermore, JH295 has no impact on bipolar spindle assembly or the spindle assembly checkpoint mechanism.
  • $446
5 days
Size
QTY
PHA-680626
T69296398493-74-8
PHA-680626 is a potent and selective PLK inhibitor. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases. PHA-680626 inhibits Plk1 (IC50 = 0.53 μM), Plk2 (IC50 = 0.07 μM) and Plk3 (IC50 = 1.61 μM).
  • $1,520
6-8 weeks
Size
QTY
AAPK-25
T102152247919-28-2
AAPK-25 is a potent and selective Aurora/PLK dual inhibitor with anti-tumor activity, which can cause mitotic delay and arrest cells in prometaphase, followed by a surge in apoptosis. AAPK-25 targets Aurora-A/-B/-C with Kd values ranging from 23-289 nM, a
  • $97
In Stock
Size
QTY
CYC-116
T6458693228-63-6
CYC116 is a potent inhibitor of Aurora A/B with Ki of 8.0 nM/9.2 nM, is less potent to VEGFR2 (Ki of 44 nM), with 50-fold greater potency than CDKs, not active against PKA, Akt/PKB, PKC, no effect on GSK-3α/β, CK2, Plk1 and SAPK2A. Phase 1.
  • $51
In Stock
Size
QTY
Plk1 PBD-IN-143
T71718923783-24-8
Plk1 PBD-IN-143 is a novel Inhibitor of the Polo-Box Domain of Polo-like Kinase 1 (Plk1 PBD).
  • $1,520
6-8 weeks
Size
QTY
Mps1-IN-2
T18391228817-38-6
Mps1-IN-2 is a potent, selective and ATP-competitive dual Mps1/Plk1 inhibitor.
  • $33
In Stock
Size
QTY
JRN73958
T70244171773-95-8
JRN73958 is an important precursor for the synthesis of scytonemin, also called Reduced scytonemin. Scytonemin is a biological pigment synthesized by many strains of cyanobacteria, including Calothrix sp., Lyngbya aestuarii, and others. Scytonemin is also a potent PKL1 inhibitor, which inhibits cell proliferation and arrests cell cycle through downregulating Plk1 activity in many cancel cells. Scytonemin was able to inhibit the proliferation of three myeloma cells in a dose-dependent manner, while U266 was the most sensitive one to scytonemin. Scytonemin , representing a novel Plk1 inhibitor, induced the inhibition of cell growth and cell cycle arrest in multiple myeloma cells by specifically decreasing Plk1 activity. This product has no formal name at the moment. For the convenience of communication, a temporary code name was therefore proposed according to MedKoo Chemical Nomenclature (see web page: https://www.medkoo.com/page/naming).
  • $1,820
8-10 weeks
Size
QTY
GW843682X
T15454660868-91-7
GW843682X (GW843682) is a selective and ATP-competitive inhibitor of PLK1 and PLK3 (IC50s = 2.2 nM and 9.1 nM).
  • $32
In Stock
Size
QTY
Volasertib trihydrochloride
T41100946161-17-7
Volasertib (BI 6727) trihydrochloride is a dihydropteridinone derivative that exhibits potent and selective inhibition of Polo-like kinase 1 (PLK1), PLK2, and PLK3. It acts as an orally active ATP-competitive inhibitor with an IC50 of 0.87 nM against PLK1. Additionally, Volasertib trihydrochloride demonstrates IC50 values of 5 nM and 56 nM against PLK2 and PLK3, respectively. Its mechanism of action includes inducing mitotic arrest and apoptosis. Furthermore, Volasertib trihydrochloride has been shown to possess significant antitumor activity in various cancer models.
  • $970
Backorder
Size
QTY
Rigosertib sodium
T5818592542-60-4
Rigosertib sodium (ON-01910), a non-ATP-competitive inhibitor of PLK1(IC50=9 nM), exhibits 30-fold higher specificity activity over Plk2 and no effect on Plk3.
  • $34
In Stock
Size
QTY
ZM-447439
T6077331771-20-1
ZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective for Aurora A/B than MEK1, Src, Lck and has little effect against CDK1/2/4, Plk1, Chk1, etc.
  • $45
In Stock
Size
QTY
FOXM1-IN-1
T73172
FOXM1-IN-1 is a potent FOXM1 inhibitor with an IC 50 value of 2.65 µM. FOXM1-IN-1 shows antiproliferative activity. FOXM1-IN-1 decreases the the expression of FOXM1, PLK1 , CDC25B protein .
  • $1,520
6-8 weeks
Size
QTY
TAK-960 dihydrochloride
T72269
TAK-960 dihydrochloride is an orally administered, selective polo-like kinase 1 (PLK1) inhibitor, exhibiting a potent IC 50 of 0.8 nM. It also targets PLK2 and PLK3 with IC 50 values of 16.9 and 50.2 nM, respectively. This compound effectively inhibits the proliferation of a broad range of cancer cell lines and demonstrates substantial efficacy against various tumor xenografts.
  • $89
5 days
Size
QTY
YLT-11
T73471
YLT-11 is a potent, selective, and orally active inhibitor of polo-like kinase 4 (PLK4), exhibiting dissociation constant (Kd) values of >10000 nM for PLK1, 653 nM for PLK2, >10000 nM for PLK3, and 5.2 nM for PLK4, respectively. It demonstrates antiproliferative effects, induces apoptosis, and causes cell cycle arrest at the G2/M phase, highlighting its anticancer activity.
  • $1,520
6-8 weeks
Size
QTY
Poloxipan
T711561239513-63-3
Poloxipan is a potent and pan-specific PLK1 inhibitor. In vitro, Poloxipan has IC50 3.2 uM (Plk1); 1.7 uM (Plk2); and 3 uM (Plk3). Poloxipan showed minor inhibition over FHA dommain of Chk2, S2 domian of STAT1, STAT5b, Lck, etc.
  • $1,520
6-8 weeks
Size
QTY
JH295 hydrate
T61061
JH295 hydrate is a potent, irreversible and selective NIMA-related kinase 2 (Nek2) inhibitor that inhibits cellular Nek2 by Cys22 alkylation (IC50 = 770 nM). JH295 hydrate is not active against the mitotic kinases, Cdk1, Aurora B or Plk1, and does not interfere with bipolar spindle assembly or the spindle assembly checkpoint [1].
  • $2,210
10-14 weeks
Size
QTY
(E/Z)-Rigosertib sodium
T60701225497-78-8
ON-01910 is a non-ATP-competitive PLK1 inhibitor(IC50 of 9 nM, in a cell-free assay). It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Rigosertib inhibits PI3K/Akt pathway and activates oxidative stress signals. Rigosertib induces apoptosis in various cancer cells.It is a synthetic benzyl styryl sulfone analogue with potential antineoplastic activity.
  • $34
In Stock
Size
QTY
HMN-214
T2438173529-46-9
HMN-214 (IVX-214) is a potent PLK1 inhibitor with an average IC50 of 0.12 μM.
  • $34
In Stock
Size
QTY
Rigosertib
T16750592542-59-1
Rigosertib (ON-01910) is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM). Rigosertib is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition of the PI3 kinase/Akt pathway, promotes the phosphorylation of histone H2AX and induces G2/M arrest in the cell cycle.
  • $34
In Stock
Size
QTY
BI-4834
T68463876371-13-0
BI-4834 is a potent and selective Polo-like kinase 1 (PLK1) inhibitor. BI-4834 is also analogue (or Me-Too) of BI-2536. In vitro test shows that BI 4834 inhibits PLK1 with IC50=7.6 nm, but with higher selectivity over the related enzyme PLK3 (IC50 198.4 nm) as BI-2536.
  • $1,670
6-8 weeks
Size
QTY
SBE13
T62591775294-82-1
SBE13 is a selective and potent inhibitor of Plk1 (IC50: 200 pM). SBE13 has a weak effect on Plk2 or Plk3 with IC50 values of >66 μM and 875 nM respectively.
  • $1,520
6-8 weeks
Size
QTY
ZK-Thiazolidinone
T68428891849-87-9
ZK-Thiazolidinone, also known as TAL, is an ATP-competitive inhibitor of PLK1. In vitro, ZK-Thiazolidinone counteracts the role of Plk1 in previously established functions, notably, sister chromatid separation, centrosome maturation, and bipolar spindle assembly. In vivo, ZK-Thiazolidinone selectively inhibits PLK1 and causes a prometaphase-like mitotic (G2–M) arrest. ZK-Thiazolidinone inhibits human PLK1 (IC50, 19± 12 nM) and various human and mouse tumor cell lines (IC50, 0.2–1.3 μM). ZK-Thiazolidinone impairs centrosome maturation.
  • $2,870
10-14 weeks
Size
QTY
CAP-53194
T23849660817-08-3
CAP-53194 is a selective Plk1 inhibitor.
  • $1,520
6-8 weeks
Size
QTY
PLK1/BRD4-IN-1
T640582412707-81-2
PLK1/BRD4-IN-1 (9b) is an orally active dual inhibitor of PLK1 (IC50: 22 nM) and BRD4 (IC50: 109 nM). It has been shown to have good anti-tumour effects in vivo.
  • $1,520
8-10 weeks
Size
QTY
CC260
T358742411088-26-9
CC260, a selective inhibitor for PI5P4Kα and PI5P4Kβ with Kis of 40 nM and 30 nM respectively, exhibits minimal to no inhibition against other protein kinases like Plk1 and RSK2. It is applicable in the research of cell energy metabolism, diabetes, and cancer[1].
  • $1,370
6-8 weeks
Size
QTY
TC-S 7005
T170081082739-92-1
TC-S 7005 is an effective inhibitor of Polo-like kinases (IC50s: 214 nM, 4 nM and 24 nM for Plk1, Plk2, and Plk3).
  • $52
In Stock
Size
QTY
HPN-01
T11573928655-63-4
HPN-01 is a selective IKK inhibitor (pIC50s: 6.4, 7.0, and <4.8 for IKK-α, IKK-β, and IKK-ε). HPN-01 displays greater 50-fold selectivity over a panel of more than 50 other kinases, including ALK5, CDK-2, ErbB2, EGFR, GSK3β, Src, PLK1, and VEGFR-2.
  • $916
6-8 weeks
Size
QTY